<DOC>
	<DOCNO>NCT00955773</DOCNO>
	<brief_summary>The purpose study determine recommend dose regimen orally administer MEK inhibitor GSK1120212 dose combination everolimus subject solid tumor . The escalation part study determine MTD . The combination explore expansion part subject metastatic pancreatic cancer . In addition , subject KRAS mutant non-small cell lung cancer enrol .</brief_summary>
	<brief_title>A Study GSK MEK Inhibitor GSK1120212 Everolimus Cancer Subjects</brief_title>
	<detailed_description>MEK112110 dose-escalation , open-label study determine recommend dose regimen orally administer MEK inhibitor GSK1120212 dose combination everolimus subject solid tumor . This accomplished use dose-escalation procedure start low dos GSK1120212 everolimus . Dose escalation continue base predefined parameter maximum tolerate dose identify . The recommended dos regimen select base safety pharmacokinetic profile . The clinical activity GSK1120212 dose combination everolimus explore expansion cohort consist 20 subject metastatic pancreatic cancer . In addition substudy conduct 40 subject KRAS-mutant non-small cell lung cancer .</detailed_description>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Capable give write informed consent , include compliance requirement restriction list consent form . Age 18 year old old able swallow oral medication . Performance Status score 0 1 accord Eastern Cooperative Oncology ( ECOG ) scale Dose Escalation Cohort . Subjects ECOG 2 enrol expansion cohort . Tumor Type criterion list protocol Fasting glucose &lt; 126mg/dL Male subject must agree use one contraception method list protocol . A female subject eligible participate nonchildbearing potential , childbearing potential must use protocol define contraception method . Calcium phosphate product less equal 4.0 mmol2/L2 ( 50 mg2/dL2 ) Adequate organ system function define protocol . Malignancies related HIV solid organ transplant . Primary malignant brain tumor . Chemotherapy , radiotherapy , immunotherapy within 28 day ( 42 day prior nitrosoureas mitomycin C ) prior first dose GSK1120212 . Chemotherapy regimens give continuously weekly basis limit potential delayed toxicity permit approval GSK Medical Monitor dose agent terminate least 14 day prior first dose GSK1120212 . Use investigational anticancer drug within 28 day 5 halflives , whichever short precede first dose GSK1120212 long minimum 14 day pass last dose prior investigational anticancer drug first dose GSK1120212 . Previous treatment mTOR inhibitor unless approve GSK Medical Monitor . Previous treatment GSK1120212 . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate study drug , DMSO , excipients . ( To date know FDA approve drug chemically relate GSK1120212 ) . Use prohibited medication ( define protocol ) . Current use anticoagulant ( e.g . warfarin , heparin ) therapeutic level within seven day prior first dose GSK1120212 . Low dose ( prophylactic ) low molecular weight heparin ( LMWH ) permit provided subject 's PT PTT meet entry criterion . Subjects require therapeutic level LMWH must receive approval GSK Medical Monitor monitor appropriately clinically indicate . Gastrointestinal disease predict interfere absorption oral drug , systemic disease , major surgery , social/psychological issue opinion investigator would jeopardize compliance protocol . History retinal vein occlusion ( RVO ) central serous retinopathy ( CSR ) . Predisposing factor RVO include uncontrolled hypertension , uncontrolled diabetes , uncontrolled hyperlipidemia , coagulopathy . Visible retinal pathology assess ophthalmologic exam consider risk factor RVO CSR . Intraocular pressure &gt; 21mm Hg measure tonography . Glaucoma diagnose within 1 month prior study Day 1 . Symptomatic untreated leptomeningeal brain metastasis spinal cord compression . Subjects previously treat condition asymptomatic corticosteroid least two week permit . Subjects permit receive enzyme induce antiepileptic drug ( EIAEDs ) . Unresolved toxicity great common terminology criterion adverse event ( CTCAE ) grade 1 previous anticancer therapy except alopecia ( applicable ) unless agree GSK Medical Monitor Investigator . History acute coronary syndrome ( include unstable angina ) , coronary angioplasty , stenting within past 24 week . QTc interval â‰¥ 480 msec . Class II , III , IV heart failure define New York Heart Association ( NYHA ) functional classification system . Pregnant lactate female . History active hepatitis B C. History HIV infection . Subjects chronic antifungal therapy . Unwillingness inability follow procedure outline protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>GSK1120212 , everolimus , solid tumor , pancreatic cancer , non-small lung cancer , KRAS-mutant</keyword>
	<keyword>cancer</keyword>
</DOC>